Medical Meetings

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Dec
18
Daratumumab, Bortezomib, and Dexamethasone VS Bortezomib and Dexamethasone for RRMM Patients: An Update of Overall Survival in Castor
Daratumumab (D) is a human monoclonal antibody targeting CD38 that is approved as monotherapy and in combination with immunomodulatory drugs (lenalidomide or pomalidomide) or a proteasome inhibitor ((...)
Dec
18
Impact of Next-Generation Flow MRD Monitoring in Multiple Myeloma: Results from the Pethema/GEM2012 Trial
MRD is an established biomarker to evaluate treatment efficacy, define patients at risk based on persistent MRD, and eventually, act as surrogate for prolonged survival based on sensitive MRD-(...)
Dec
18
Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA Patients with NDMM in the Connect® MM Registry
t(11;14) is a common cytogenetic abnormality found in ~15% of patients (pts) with MM. Although t(11;14) is historically associated with favorable or neutral outcomes in MM (Sawyer 2011; Moreau 2007(...)
Dec
14
Subcutaneous Delivery of Daratumumab in Patients with RRMM
Daratumumab (DARA), a CD38-targeted human monoclonal antibody, is approved as monotherapy and in combination with bortezomib (proteasome inhibitor; PI) or immunomodulatory drugs (IMiD; lenalidomide(...)
Dec
14
Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with RR Amyloidosis
AL amyloidosis has a very poor prognosis with a variable median survival of 12 to 18 months depending largely on the severity of organ involvement. Current treatment focusing on eliminating the(...)
Dec
13
Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone Induces a High Response Rate in Patients with Relapsed MM
Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1). Twice weekly (BIW) bortezomib in combination with dexamethasone (Vd)(...)